Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

Serplulimab (Hetronifly, Accord Healthcare) 'in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES‑SCLC)'.

The dosage schedule is available in the summary of product characteristics for serplulimab.

The list price of serplulimab is £1,321.83 per 100‑mg vial (excluding VAT; BNF online accessed May 2026).

The company has a commercial arrangement. This makes serplulimab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on Accord Healthcare's Environmental, Social and Governance (ESG) webpage.